A previous study by Gorre et al. [16] reported that there was no significant relationship between JAK2 gene expression and hematological or molecular responses, but an increase in JAK2 gene expression occurred when the diagnosis of CML was made and during treatment. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.